UCB (OTCMKTS:UCBJY) Hits New 1-Year Low – Time to Sell?

Shares of UCB SA (OTCMKTS:UCBJY) reached a new 52-week low during trading on Tuesday. The stock traded as low as $112.6450 and last traded at $112.99, with a volume of 65773 shares changing hands. The stock had previously closed at $115.22.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on UCBJY shares. Zacks Research downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 16th. Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 15th. Finally, Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

UCB Stock Up 0.6%

The firm has a fifty day simple moving average of $123.42 and a two-hundred day simple moving average of $137.16.

About UCB

UCB SA is a Belgium-based biopharmaceutical company that discovers, develops and commercializes medicines for severe diseases, with a primary focus on neurology and immunology. The company serves patients and healthcare professionals in markets around the world through its research, manufacturing and commercial operations.

UCB’s medicines include Bimzelx (bimekizumab), used to treat several inflammatory conditions; Cimzia (certolizumab pegol), an immunology therapy; and Fintepla (fenfluramine), a treatment for certain severe epileptic syndromes.